Infectious Disease
Antibiotic Alternatives
Immunology
Oncology
Peter Hanson
Centrexion is developing a pipeline of non-opioid, non-addictive treatments to manage pain in people and animals. Peter started his career as a practicing veterinarian and has spent the last 21 years in industry. At Merck and then Merial he was the project leader for two global programs that led to new pain management products for osteoarthritis in dogs and horses. He subsequently held leadership roles for pharmaceutical R&D and project & portfolio management before moving to Abbott Animal Health where he was head of R&D & medical affairs. Peter received his BA and DVM from the University of Minnesota and completed a large animal surgical residency, MS and PhD at the University of Wisconsin-Madison.
Scott Brown
Kristin Bloink
Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D. She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector. She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.
Brian Kopp
Brian Kopp is a Partner at Stonehaven Consulting AG. He has 20 years of experience in Healthcare with Eli Lilly and Company, and 7 years of experience in Automotive with General Motors. Since 2007, Brian has served as CFO and V.P. of Operations and Strategy with Elanco Animal Health, a division of Eli Lilly and Company. Over this period, Elanco has grown Revenues from $700 million to over $3 billion, emerged as a top tier player in the industry, achieved top tier Operating margins, experienced significant expansion of business lines, global capabilities, and overall value. This significant growth was achieved by executing on an aggressive transformation agenda that included capitalizing on a mix of organic and inorganic opportunities. After 27 years working in increasingly relevant roles within Corporate settings, Brian is excited by the opportunity to take his experiences and insights and help Animal Health partners develop and/or realize their strategic goals.
Richard Dennett
Tim Adetona, M.Sc., D.PH
Tim has a broad regulatory expertise of close to 20 years’ experience (5 as Consultant) in addressing and obtaining regulatory authorization for various life-science products including drugs, biologics and innovative nutritional products in Europe, as well as statutory regulatory requirements in global markets including the USA and emerging markets.
Tim has acquired significant knowledge of Swiss regulations and Swissmedic procedures and has successfully managed a number of MAA submissions for drugs and biologics. Tim has substantial experience in all steps of product development from preclinical to life-cycle management, including those involving specialized conditions as orphan drug designations, accelerated or fast-track assessment procedures and compassionate use programs.
Tim also has responsibility for the management of projects involving the design and implementation of global regulatory strategies for the development, evaluation and marketing of nutritional and innovative food-drug borderline products. Tim is equally well versed in regulatory engagements involved with the development of Personal, Health and Beauty Care products (cosmetics, deodorants and antiperspirants), as well as Medical Devices and OTC medicines.
Prior to joining VCLS, Tim was Regulatory Affairs Director, Consumer Health Care International (CHCI) for Vifor Pharma, where he provided directional leadership for the implementation of all aspects of Regulatory Affairs related to Consumer Health Care products in global markets and successfully expanded the experience he had gained as Senior Regulatory Affairs Manager for Procter & Gamble.